FCRN antagonists and methods of use

Patent metadata

Field	Value
Publication number	US-10316073-B2
Application number	US-201414580771-A
Country	US
Kind code	B2
Filing date	Dec 23, 2014
Priority date	Dec 24, 2013
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.

First claim

We claim:

1. An isolated FcRn-antagonist consisting of a variant Fc region, wherein said variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 2.

2. A pharmaceutical composition comprising the FcRn-antagonist of claim 1 and a pharmaceutically acceptable carrier or excipient.

3. An isolated FcRn-antagonist consisting of a variant Fc region, wherein said variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 2, and wherein an N-linked glycan having a bisecting GleNac is attached to EU position 297 of the Fc domains.

4. A composition comprising a plurality of FcRn-antagonist molecules of claim 3 , wherein at least 50% of the molecules of the composition consist of the FcRn-antagonist of claim 3 .

5. A pharmaceutical composition comprising the FcRn-antagonist of claim 3 and a pharmaceutically acceptable carrier or excipient.

6. An isolated FcRn-antagonist consisting of a variant Fc region, wherein said variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 3.

7. A pharmaceutical composition comprising the FcRn-antagonist of claim 6 and a pharmaceutically acceptable carrier or excipient.

8. An isolated FcRn-antagonist consisting of a variant Fc region, wherein said variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 3, and wherein an N-linked glycan having a bisecting GlcNac is attached to EU position 297 of the Fc domains.

9. A composition comprising a plurality of FcRn-antagonist molecules of claim 8 , wherein at least 50% of the molecules of the composition consist of the FcRn-antagonist of claim 8 .

10. A pharmaceutical composition comprising the FcRn-antagonist of claim 8 and a pharmaceutically acceptable carrier or excipient.

Assignees

• Argenx Bvba
• Univ Texas

Inventors

• Ulrichts Peter
• Blanchetot Christophe
• Dreier Torsten
• De Haard Johannes
• Ward Ober E Sally
• Ongenae Nicolas G H

Classifications

• A61P7/06

  Antianaemics · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title